β-Catenin-IN-6 is an inhibitor of the canonical Wnt/β-catenin signaling pathway, effectively impeding the proliferation of human colorectal cancer cells and demonstrating efficacy in a β-catenin/RK3E mouse model [1] [2].

β-Catenin-IN-6 (compound 9) demonstrates inhibitory effects on LoVo and HT29 cells after a 24-hour exposure, with IC50 values of 1.4 μM and 1.37 μM, respectively. This compound exhibits growth inhibition in several human colorectal cancer cell lines [1].

β-catenin-IN-6 (compound 9) exhibits poor bioavailability [1]. Administered intraperitoneally at a dosage of 18.75 mg/kg daily for seven days, it reduces tumor volume in mice without affecting body weight [1]. At 150 mg/kg once weekly, β-catenin-IN-6 (compound 13) inhibits ectopic tumor growth in the β-catenin/RK3E mouse model [2].